SOURCE: Xtalks

Xtalks Webinars

March 31, 2015 07:05 ET

Evaluation of Atrial Fibrillation and Other Arrhythmias Within Clinical Trials and Clinical Practice, New Webinar Hosted by Xtalks

TORONTO, ON--(Marketwired - March 31, 2015) - This webinar will discuss trends in continuous ECG monitoring and the implications for clinical trials of both medical device and therapies for cardiovascular, hematologic, metabolic, CNS or any other indications, with an emphasis on atrial fibrillation and other cardiac arrhythmias. The live broadcast takes place on Tuesday, April 28, 2015 at 11am EDT / 4pm BST (UK GMT +1).

Drug Developers, Scientists and Regulators and Practicing Cardiologists are starting to pay more attention to high throughput data related to cardiovascular health of subjects and patients. In clinical trials, the need for ECG monitoring crosses all phases of clinical drug/device development (Phases I - IV). There is a need for both real-time and longer-term monitoring periods, particularly for assessment of Atrial Fibrillation, Atrial Flutter, Ventricular Fibrillation and Ventricular Tachycardia and other serious rhythm disturbances.

Atrial Fibrillation (AF), the most common type of arrhythmia, is a serious health risk, particularly in the rapidly growing aged population. AF occurs if rapid, disorganized electrical signals cause the heart's two upper chambers - the atria- to lose coordinated contraction. AF happens with varying frequency. Often it becomes an ongoing, long-standing heart problem that persists for years. AF treatment costs are approaching $7Billion per year as AF is associated with heart failure and occurs in 15-20% of cryptogenic stroke patients. Early diagnosis, achieved with new ECG monitoring modalities, with subsequent early treatment improves health, lowers the risk of arrhythmia-related complications and lowers long-term healthcare costs. It is imperative that there are new drugs and devices available to prevent and/or minimize the impact of AF and other serious arrhythmias.

Arrhythmia and syncope are two important conditions that may be linked. In AF, many occurrences are asymptomatic but still represent a threat to the patient due to the risk of cerebral and systemic embolism. This risk of embolization may occur in patients on drug therapy and also to those after catheter ablation. Patients with AF and with syncope need ECG monitoring to provide early diagnosis which may lead to life-altering medical care. Throughout the drug development process it is also very important to anticipate and minimize safety concerns related to potential AF or other serious arrhythmias.

Join featured speakers Dr. Polina Voloshko, Chief Medical Officer at Cardiocore, and Dr. Wayne Derkac, Vice President of Medical Affairs at BioTelemetry, to learn what we in the clinical trials industry can do to help identify and treat AF and other heart rhythm irregularities with properly utilized continuous monitoring used in clinical studies aimed at developing new treatment options and changing existing treatment paradigms. Cardiocore has profound professional expertise in Cardiovascular Disease testing, and Arrhythmia detection evaluation, in particular. World renowned experts in study design and analysis will provide insights into AF and how it can be continuously monitored as part of your clinical trial. Various types of monitoring devices will be covered, with a description of which type of continuous monitoring device best suits which type of clinical trial. The effectiveness of continuous monitoring in detecting heart rhythm events (arrhythmias, including AF) depends on its type, continuity and duration. New technologies and future directions in continuous monitoring will be explored.

For more information about this event visit: Evaluation of Atrial Fibrillation and Other Arrhythmias within Clinical Trials and Clinical Practice

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx

Image Available: http://www.marketwire.com/library/MwGo/2015/3/30/11G037029/Images/CC_BT_Subsidiary_Logo2-805074587713.jpg

Contact Information